25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future
出版年份 2021 全文链接
标题
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future
作者
关键词
-
出版物
GUT
Volume -, Issue -, Pages gutjnl-2019-320022
出版商
BMJ
发表日期
2021-01-13
DOI
10.1136/gutjnl-2019-320022
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis
- (2020) S Ben-Horin et al. Journal of Crohns & Colitis
- S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study
- (2020) Silvio Danese et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
- (2019) Byong Duk Ye et al. LANCET
- Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
- (2019) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study
- (2019) Sophie E. Berends et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s disease patients
- (2019) Anne S. Strik et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn’s Disease Compared with Reactive Monitoring
- (2019) Amit Assa et al. GASTROENTEROLOGY
- Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
- (2019) Nicholas A Kennedy et al. Lancet Gastroenterology & Hepatology
- Letter: should we intensify infliximab in acute severe ulcerative colitis?
- (2019) David Laharie et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
- (2019) Aleksejs Sazonovs et al. GASTROENTEROLOGY
- Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-Up in the Pyramid Registry
- (2018) Geert D’Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease
- (2018) Kenji Watanabe et al. Clinical Gastroenterology and Hepatology
- Acute Liver Failure from Tumor Necrosis Factor-α Antagonists: Report of Four Cases and Literature Review
- (2018) Beverley Kok et al. DIGESTIVE DISEASES AND SCIENCES
- Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
- (2018) Geert D’Haens et al. GASTROENTEROLOGY
- Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy—a Post-hoc analysis
- (2018) Jean Frederic Colombel et al. Clinical Gastroenterology and Hepatology
- Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy
- (2018) Toer W. Stevens et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
- (2017) Magali Lemaitre et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme
- (2017) Violeta Razanskaite et al. Journal of Crohns & Colitis
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
- (2016) Louise K Mercer et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
- (2016) Johannan F. Brandse et al. Clinical Gastroenterology and Hepatology
- Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
- (2016) Miguel Regueiro et al. GASTROENTEROLOGY
- The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
- (2016) Geoffrey C. Nguyen et al. GASTROENTEROLOGY
- Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study
- (2016) Lisa J. T. Smits et al. Journal of Crohns & Colitis
- Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis
- (2015) P. De Cruz et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease
- (2015) Isabelle Cleynen et al. ANNALS OF INTERNAL MEDICINE
- An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
- (2015) David J. Gibson et al. Clinical Gastroenterology and Hepatology
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
- (2015) Johannan F. Brandse et al. GASTROENTEROLOGY
- Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease
- (2015) Paolo Biancheri et al. GASTROENTEROLOGY
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- Crohn's disease management after intestinal resection: a randomised trial
- (2015) Peter De Cruz et al. LANCET
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)
- (2013) Pieter Dewint et al. GUT
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children
- (2012) Jeffrey S. Hyams et al. GASTROENTEROLOGY
- Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
- (2012) Paul Rutgeerts et al. GASTROENTEROLOGY
- Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
- (2012) Xavier Hébuterne et al. GUT
- Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease
- (2012) S. Schreiber et al. Journal of Crohns & Colitis
- Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis
- (2011) Jeffrey Hyams et al. Clinical Gastroenterology and Hepatology
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
- (2010) Stefan Schreiber et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
- (2009) Filip Baert et al. GASTROENTEROLOGY
- Adalimumab for the treatment of fistulas in patients with Crohn's disease
- (2009) J-F Colombel et al. GUT
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started